Company intelligence / Profile preview

Geneyork Pharmaceutical

Princeton, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Geneyork Pharmaceutical is a privately held specialty pharmaceutical company focused on development, contract manufacturing, and commercialization of generic small‑molecule finished dosage forms, including a U.S.‑launched generic version of prednisone tablets (generic Deltasone). Geneyork reports a portfolio of more than 40 specialty products, nine approved ANDAs, six additional ANDAs filed with FDA, and several in‑licensed or acquired ANDAs for oral solid extended‑release, topical, and complex injectable products.[1][3][5]

Therapeutic areas: HematologyImmunologyDermatologyPulmonologyRheumatologyOncologyOphthalmology
Modalities: Small molecule
Industry: Biotech

Partnerships

Lannett Company

Beyond the preview

Go deeper on Geneyork Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Geneyork Pharmaceutical.

Explore the full profile